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ABSTRACT Although preoperative portal vein emboli-
zation (PVE) is an effective means to increase future
remnant liver (FRL) volume, little has been published on
possible adverse effects. This review discusses the clinical
and experimental evidence regarding the effect of PVE on
tumor growth in both embolized and nonembolized liver
lobes, as well as potential strategies to control tumor pro-
gression after PVE. A literature review was performed
using MEDLINE with keywords related to experimental
and clinical studies concerning PVE, portal vein ligation
(PVL), and tumor growth. Cross-references and references
from reviews were also checked. Clinical and experimental
data suggest that tumor progression can occur after pre-
operative PVE in embolized and nonembolized liver
segments. Clinical evidence indicating possible tumor
progression in patients with colorectal metastases or with
primary liver tumors is based on studies with small sample
size. Although multiple studies demonstrated tumor pro-
gression, evidence concerning a direct increase in tumor
growth rate as a result of PVE is circumstantial. Three
possible mechanisms influencing tumor growth after PVE
can be recognized, namely changes in cytokines or growth
factors, alteration in hepatic blood supply and an enhanced
cellular host response promoting local tumor growth after
PVE. Post-PVE chemotherapy and sequential transcatheter
arterial chemoembolization (TACE) before PVE have been
proposed to reduce tumor mass after PVE. We conclude
that tumor progression can occur after PVE in patients with
colorectal metastases as well as in patients with primary
liver tumors. However, further research is needed in order
to rate this risk of tumor progression after PVE.
Preoperative portal vein embolization (PVE) is an
accepted intervention in patients requiring major liver
resection in whom the estimated future remnant liver
(FRL) is too small to allow safe resection.1,2 PVE induces
atrophy of the embolized, tumor-bearing liver lobe while
compensatory hypertrophy of the nonembolized lobe
occurs, thereby increasing FRL volume and function.1–6
Portal vein occlusion by either embolization (PVE) or
ligation (PVL) has proven useful to reduce risk of post-
operative liver dysfunction and enables resection in
patients previously deemed unresectable due to a marginal
FRL.7–14 FRL volume smaller than 25–30% of total pre-
operative liver volume is generally considered insufficient
in patients with normal liver parenchyma.15–17 In patients
with a compromised liver, the cutoff value for performing
safe resection is more variable and PVE is usually under-
taken when the FRL is smaller than 40% of total liver
volume.10,12,16
While experiences with PVE have accumulated, there is
growing evidence that PVE stimulates not only the growth
of the FRL but also affects tumor size in both embolized
and nonembolized liver segments.18–20 This review dis-
cusses the clinical and experimental evidence regarding the
effect of PVE on tumor growth in the nonembolized and
embolized liver lobes, as well as potential strategies to
control tumor progression after PVE.
THE EFFECT OF PVE ON TUMOR GROWTH
Table 1 provides an overview of the studies describing
tumor progression after preoperative PVE. Elias et al. were
among the first to describe the potential of intrahepatic
tumor enlargement after PVE.18 Their conclusion was
based on five patients with known tumors in the nonem-
bolized liver lobes. All patients had measurable tumors in
the left (nonembolized) liver lobes before PVE, which
provided the opportunity to measure tumor enlargement. In
four of the five patients tumor size increased after PVE.
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One patient with impaired liver function showed no
increase in tumor volume. The authors concluded that, in
patients with normal liver parenchyma, the growth rate of
metastases is more rapid than the hypertrophy of the sur-
rounding liver parenchyma. Although the increase in tumor
size in this study was impressive, no tumor growth rate
before PVE was investigated, making it impossible to draw
conclusions regarding direct stimulation of tumor growth
by PVE. The study only demonstrates that tumor size can
increase in the waiting period between PVE and resection.
An increased growth rate of liver metastases as a result of
portal vein diversion was however demonstrated in a
murine model in which the portal vein to one side of the
liver was ligated.21 Tumor increase in the nonembolized
segments is of special interest in patients with bilateral
liver metastases. Although in these patients a right hemi-
hepatectomy with simultaneous wedge resection in the left
liver has been described after right PVE, the outgrowth of
lesions in the left liver in the time between right PVE and
resection poses a potential threat in respect with resect-
ability.22 A two-staged resection in combination with PVE
can successfully be applied in some of these patients.23 In
the first stage resection removal of all tumor mass located
in the (future) nonembolized liver segments is required
before the actual PVE (or PVL) in order to prevent rapid
tumor enlargement after portal vein occlusion.23 Subse-
quently, major hepatectomy can be performed several
weeks after the portal vein occlusion.
The time between PVE and follow-up computed
tomography (CT) to recalculate FRL volume can also be
viewed as a diagnostic window in which clinical outgrowth
of micrometastases in the nonembolized lobe may occur.
Small metastases in the nonembolized lobe, not detectable
on a CT scan before embolization, may become visible
after PVE as a result of the potential tumor-growth-stim-
ulating environment provided by PVE. Such a finding will
render the patient unresectable or will require reconsider-
ation of management (Fig. 1).
Several studies have described the effect of preoperative
PVE on progression of colorectal metastases in the em-
bolized liver segments. Kokudo et al. were the first to
report increased proliferative activity of colorectal liver
metastases.20 This is the largest case series concerning this
issue, including 18 patients with prior PVE who were
TABLE 1 Studies describing the effect of preoperative PVE on tumor progression
Tumor type Tumor location No. of
patients
Increase in tumor volume (%) Increase in
growth rate (%)
Elias et al.18 Liver metastases Nonembolized liver segments 5 215% (-30%, 970%)a –
Hayashi et al.24 HCC Embolized liver segments 6 – 265% (200–746%)a
CCC Embolized liver segments 2 – 116% (100–132%)a
Kokudo et al.20 CRM Embolized liver segments 15 20.8%b –
Both embolized and
nonembolized
3 3.0% (2.5–6.3%)a (embolized) –
9.7% (0.5–42.1%)a (nonembolized)
Barbaro et al.19 CRM Embolized liver segments 6 84.4% (62.4–562%)a –
Carcinoid tumor Embolized liver segments 3 0 –
CRM colorectal metastasis, HCC hepatocellular carcinoma, CCC cholangiocarcinoma
a Median (minimum, maximum)
b Mean
FIG. 1 Example of a patient with
multiple colorectal metastases in the
right liver lobe requiring an extended
right hemihepatectomy. No lesions in
segment 2 and 3 were visible (a). Due
to a small FRL volume, PVE was
performed. CT scan 3 weeks after PVE
revealed multiple metastases in
segments 2 and 3 excluding this patient
from resection (b)
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compared with 29 patients who were resected without
PVE. One patient in the PVE group received preoperative
intra-arterial chemotherapy. No use of neoadjuvant che-
motherapy was described in the other patients. Mean tumor
volume, measured by CT volumetry, was significantly
increased by 20.8% in the 3-week interval after PVE.
However, the growth of liver tumors in the group without
PVE was not assessed, and tumor growth rate before PVE
was not measured. Instead, the proliferation of metastatic
lesions measured by Ki-67 labeling index after PVE was
compared with the proliferation rate of metastatic lesions in
the control group undergoing only resection. Ki-67 labeling
index was significantly higher in the PVE group. Although
the distribution of well, moderately, and poorly differen-
tiated adenocarcinoma was similar within the two groups,
tumor size was significantly larger in the PVE group, which
influences the Ki-67 labeling index. This study only dem-
onstrates that colorectal liver metastases continue to grow
in the embolized liver lobes after PVE. The evidence of
direct tumor growth stimulation by PVE is however cir-
cumstantial. Barbaro et al. confirmed the increase of tumor
volume after PVE in patients with colorectal metastases.19
In contrast, no increase in tumor volume was observed in
patients with carcinoid metastases, suggesting that tumor
characteristics are important for tumor progression after
PVE. Again no evidence is provided in this study to
demonstrate direct stimulation of tumor growth by PVE.
Figure 2 demonstrates tumor enlargement in the embolized
segments after PVE in a patient with colorectal metastases.
Data also exist that the growth of primary liver tumors
including hepatocellular carcinoma (HCC) and cholangio-
cellular carcinoma (CCC) is influenced by PVE.24 In eight
patients with primary liver tumors (six HCC, two CCC),
rate of tumor growth after PVE was compared with growth
rate of the same tumors in a period before embolization.
Tumor growth rate accelerated from 0.59 cm3/day before
PVE to 2.37 cm3/day after PVE, as measured by CT vol-
umetry. This is the first study demonstrating induction of
increased tumor growth by PVE as compared with the
growth rate before PVE in the same patients.
In a recent study, Ribero et al. retrospectively analyzed
112 PVE patients.13 Changes in tumor size were measured
in 80 patients, resulting in overall no increase in median
tumor size within all patients after PVE. The change in
95% confidence interval after PVE indicates both an
increase and a decrease in some patients. However, no
information was provided regarding the percentage of
patients with increased or decreased tumor size after PVE.
Twenty-eight patients received chemotherapy prior to PVE
and five patients received chemotherapy 2 weeks after
PVE. No differentiation was made between patients with or
without chemotherapy, and no tumor volumes were cal-
culated. Additional studies are therefore required to
precisely assess the risk of accelerated tumor growth in
patients receiving PVE.
Besides reports of tumor progression after PVE, studies
describe high percentages of patients with unresectable
disease after PVE. In the study by Ribero et al. 10 out of
the 112 patients (9%) did not undergo surgery after PVE
because of extra- or intrahepatic disease progression.13 An
additional 12 patients (11%) had unexpected extra- or
intrahepatic disease that became evident at laparotomy.
Similar percentages of tumor progression precluding
curative resection are described, with percentages ranging
from 6.4% to 33%.8,11,25,26 A recent meta-analysis
assessing the results of preoperative PVE reported that 85%
of the evaluable patients that had undergone PVE under-
went laparotomy. Of these patients, 11.3% were
unresectable due to intra- or extrahepatic tumor spread.1
The effect of tumor progression on disease-free and
overall survival is currently elusive. In the study by Kok-
udo et al. disease-free survival at 2 and 4 years in patients
who had undergone PVE was significantly poorer than in
those undergoing partial liver resection without prior PVE.
However, the two groups were different with respect to
preoperative tumor diameter and use of postoperative
FIG. 2 Example of a patient with a
large colorectal metastasis in the right
liver. CT scan 3 weeks after PVE
shows a clear increase in tumor
diameter. Total tumor volume increased
by 42%
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chemotherapy, making direct comparison impossible. In
addition, no difference in overall survival was found.
Azoulay et al. demonstrated similar survival rates after
hepatectomy with or without previous PVE. Only resected
patients were included in the survival analysis, and 33% of
the patients with previous PVE were unresectable due to
tumor progression. Survival rate in these patients was
significantly poorer.
Little evidence exists regarding the effect of PVE on the
induction of distant metastases. Breakdown and remodel-
ing of the extracellular matrix takes place especially in the
embolized, tumor-bearing liver lobes. Matrix metallopro-
teinases (MMPs) are most likely involved in this
remodeling process similar to remodeling during liver
regeneration.27 MMPs have been reported to promote
metastatic behavior in several types of tumors, including
colorectal cancer.28
MECHANISMS AFFECTING TUMOR GROWTH
AFTER PVE
Three possible mechanisms inducing tumor growth after
PVE have been proposed, namely changes in cytokines and
growth factors, alteration in hepatic blood supply, and
enhanced cellular host response promoting local tumor
growth.
Cytokines and Growth Factors
The mechanisms underlying the atrophy–hypertrophy
complex induced after PVE remain largely undetermined.
Growth factors such as interleukin (IL)-6, tumor necrosis
factor (TNF)-a, and hepatocyte growth factor (HGF) are
upregulated and play an essential role during liver regen-
eration after partial liver resection.29 The same growth
factors have been implicated in stimulating growth of
colorectal carcinoma cells in vitro.30,31 The HGF receptor
is present in almost all human colorectal carcinomas.32
Treatment of human colon carcinoma cell lines with HGF
stimulates cell growth and increases its metastatic poten-
tial.32,33 Experimental studies have shown an increase in
IL-6, TNF-a, and HGF mRNA expression in the nonli-
gated, hypertrophied liver lobes after PVL, suggesting a
similar role of these factors as in post-hepatectomy liver
regeneration.20,34–36 Local elevation of these growth fac-
tors may stimulate colorectal metastases in the non-
embolized liver segments. Interestingly, it has also been
demonstrated that HGF and IL-6, although to a lesser
extent, are upregulated in the ipsilateral liver lobes after
PVL.20,35,36 In addition, increased tissue levels of HGF
may increase plasma levels, thus stimulating the growth of
hepatic tumors in the embolized lobe.
A recent experimental study demonstrated that PVL
induced sinusoidal perfusion failure along with significant
hypoxia during the initial few days after PVL, resulting in
necrosis and apoptosis in the ligated liver tissue.37 How-
ever, most malignant tumors tolerate hypoxia quite well.38
In addition, hypoxia may induce cellular changes that can
result in more aggressive phenotypes with increased
potential for local invasive growth, distant tumor spread-
ing, and resistance to therapy.38,39 In the first days after
PVL negative regulators of hepatocyte proliferation, such
as transforming growth factor-b (TGF-b) and interleukin-1
(IL-1), are strongly expressed in the atrophic lobes.36 TGF-
b serves in normal tissue as a tumor suppressor by inhib-
iting cell proliferation. Many colorectal carcinomas,
however, are resistant to TGF-b-induced growth inhibition.
In advanced stages, TGF-b can even stimulate the prolif-
eration of colon carcinoma cells.40 In the late phase after
ligation, tissue remodeling takes place which is dominated
by cell proliferation.37 Hence, tumor proliferation may be
promoted in this late phase after PVE.
Alteration in Hepatic Blood Supply
Increased hepatic arterial blood flow after embolization
of the ipsilateral portal branch is another factor potentially
stimulating tumor growth after PVE. The liver has a dual
blood supply with about 75% being contributed by the
portal vein and 25% by the hepatic artery.41 Compensatory
increased arterial perfusion, known as the hepatic arterial
buffer response, occurs after reduction of segmental portal
blood flow.42 Clinical and experimental studies demon-
strate a significant increase in hepatic arterial blood flow in
the occluded liver lobes resulting from an increase in
common hepatic arterial flow.37,43 After portal vein
occlusion, sinusoidal perfusion is derived almost totally
from arterial blood supply.44 Because liver tumors are
mainly fed by the hepatic artery, the hepatic arterial buffer
response potentially stimulates tumor growth in the
embolized liver lobes.
Although a very likely theory, no studies as yet have
proven the involvement of the hepatic arterial buffer
response in the induction of tumor growth
Cellular Host Response Promoting Local Tumor
Growth
A third mechanism implicated in tumor growth after
PVE is the local cellular response evoked in the embolized
atrophying liver lobes.45 Studies in animal models have
demonstrated that portal vein occlusion induces an imme-
diate early gene response in both ligated and nonligated
liver lobes.35,45 Enhanced expression of several of these
genes in the atrophying liver tissue such as heat shock
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protein-70 (hsp70), heme oxygenase-1 (hmox-1), or plas-
minogen activator inhibitors (PAI-1) have a cytoprotective
effect and a role in tissue remodeling and repair.45 The
same factors have been shown to facilitate growth and
angiogenesis in solid tumors, including colon carcino-
mas.46–49 The production of these factors by the
surrounding liver parenchyma may in this manner con-
tribute to tumor progression. In addition, many tumors
including HCC and colorectal carcinomas have the poten-
tial to express hsp70 themselves.50 In some tumors,
expression of hsp70 has been related to cell proliferation,
poor prognosis, and resistance to chemotherapy.50 Similar
to the local parenchyma, tumor cells might upregulate
hsp70 in response to occlusion of portal blood flow,
thereby increasing their proliferative capacity.
STRATEGIES TO REDUCE TUMOR GROWTH
AFTER PVE
Several therapeutic strategies have been described to
prevent and even reduce tumor progression after PVE
including sequential hepatic transcatheter arterial chemo-
embolization (TACE) and PVE and post-PVE
chemotherapy.
Sequential TACE and PVE
Studies from Japan reported that additional ipsilateral
TACE before or after PVE improved the hypertrophy
response of the FRL in patients with HCC and chronic liver
disease.51,52 The rationale behind this combination was not
only to improve the regenerative capacity after PVE by
closing down arterial–portal shunts but also to reduce the
risk of tumor progression secondary to the compensatory
increase in arterial blood flow.51,53–55 Aoki et al. described
a group of 17 HCC patients who underwent PVE 7–
10 days after TACE.51 The combination generated suffi-
cient hypertrophy of the nonembolized lobes within
2 weeks. No tumor progression was noted in the waiting
time until resection as measured by CT volumetry.
Examination of the resection specimen revealed almost
complete tumor necrosis (90–100%) in ten patients (59%).
In the other patients, extent of necrosis was 50–80%. Ogata
et al. compared a group of HCC patients (n = 18) under-
going PVE 3 weeks after TACE with a group of HCC
patients who underwent only right-sided PVE in the same
period.54 Right hemihepatectomy was performed 4–
8 weeks after PVE. Mean increase in FRL volume and rate
of hypertrophy were significantly higher in the group in
which PVE was combined with TACE. Using this combi-
nation, complete tumor necrosis was achieved in 80% of
the patients compared with 5% in the PVE group. In
addition 1-, 3-, and 5-year recurrence-free survival rates
were higher in the combined group. This clearly demon-
strates that TACE combined with PVE is effective in
reducing tumor progression in HCC patients.
A drawback of the combination of TACE with PVE is the
risk of ischemic parenchymal damage. Vetelainen et al.
demonstrated that simultaneous ligation of the hepatic artery
and portal vein in rats resulted in massive liver cell necrosis
with increased systemic inflammatory response and
decreased liver function.56 An interval of 48 h between both
procedures decreased the risk of liver injury. Nakao et al.
reported, in a clinical study, that simultaneous hepatic arte-
rial and portal venous embolization resulted in necrosis and
infarction of the embolized tissue.53 Aoki et al. used inter-
vals of 7–10 days in their clinical study and described a
transient increase in liver damage parameters.51 Examina-
tion of the resection specimen showed minimal necrosis of
the liver parenchyma in the majority of patients. Two
patients however had segmental infarction in the embolized
lobes. Ogata et al. used time intervals of 3–4 weeks which
resulted in significant increase in aspartate aminotransferase
(AST)/alanine aminotransferase (ALT) levels, however
without decrease in liver function.54 The most suitable
interval between ipsilateral arterial and portal embolization
in the clinical setting remains uncertain as well as its effect in
livers compromised by steatosis or previous chemotherapy.
Although TACE is most frequently used in patients with
hepatocellular carcinoma, there are also reports indicating
its use in other liver tumors including colorectal metasta-
ses.57–59 This suggests that sequential TACE with
preoperative PVE could also be potentially beneficial in
patients with colorectal metastases. To date, however, no
study has reported the using of sequential TACE with
preoperative PVE in this category of patients.
Post-PVE Chemotherapy
With recent development of improved chemotherapeutic
agents, an increasing number of patients with metastatic
liver disease are treated with neoadjuvant chemotherapy. If
preoperative PVE is required, chemotherapy is discontin-
ued several weeks prior to embolization until surgery 3–
4 weeks thereafter, because of its alleged negative influ-
ence on the hypertrophy response.11,60,61 This allows tumor
progression to occur in the period in which chemotherapy
is discontinued in addition to the possible tumor stimulat-
ing effects of PVE. Beal et al. reported in a retrospective
study including 15 patients, of which 10 received post-PVE
chemotherapy, that hypertrophy of the FRL did occur in
the post-PVE chemotherapy group, although significantly
less compared with the nonchemotherapy group.60 Tumor
progression was seen in four of the five patients without
post-PVE chemotherapy, whereas tumor reduction was
seen in six of the ten patients with chemotherapy.
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The group of Belghiti recently demonstrated no significant
difference in hypertrophy response nor in postoperative
complications when chemotherapy was continued after
PVE.61 They therefore recommended not to disrupt a
successful chemotherapy course prior to or after portal vein
occlusion in patients with colorectal metastases. These
conclusions however, are based on a series of 20 patients,
of whom only 10 received post-PVE chemotherapy.
Covey et al. recently confirmed that continuation of
chemotherapy after PVE had no negative influence on the
hypertrophy response in a series of 100 patients including
43 patients with post-PVE chemotherapy.62 Interestingly,
significantly more patients were unresectable in the post-
PVE chemotherapy group. The reasons for unresectability
of each group were not given but, overall, 23% of the
patients were not resected due to intra- and/or extrahepatic
tumor progression. This difference can be caused by a
selection bias between the two groups because tumor size
and stage were also not provided.
Selzner et al. applied selective intrahepatic arterial
(SIHA) chemotherapy combined with portal vein ligation
for downstaging of colorectal liver metastases.63 SIHA
chemotherapy has the advantage of a high response rate
with a low rate of systemic toxicity. SIHA was started 3–
7 days after PVL in 11 patients using a catheter positioned
in the gastroduodenal artery with the tip at the junction
with the hepatic artery. Chemotherapy involved serial
administration of floxuridine for 2 weeks every 4 weeks.
The volume of liver metastases decreased by 60% within
3 months after PVL. Although this study was performed in
a highly selected group of unresectable patients, it shows
that chemotherapy is able to reduce tumor growth after
ipsilateral portal vein occlusion.
DISCUSSION
PVE as a means to induce hypertrophy of the FRL is
clearly established. Little has been reported, however, about
the negative side-effects of PVE. Several studies have
shown tumor progression in patients with colorectal
metastases as well as in patients with primary liver tumors
after PVE.18–20,24 Although the clinical studies clearly
demonstrate that tumor progression is possible in both the
embolized and nonembolized liver lobes, the evidence of
direct stimulation of tumor growth by PVE is circumstantial.
In addition the reports of increased tumor proliferation after
PVE are based on limited case series. In a larger study, no
increase in median tumor size after PVE was shown within
the total group of 80 patients.13 However, to date, there is no
information available on the percentage of patients with
increased or decreased tumor size after PVE. Additional
studies are therefore required to more precisely assess the
risk of accelerated tumor growth in patients receiving PVE.
Tumor progression after PVE creates a dilemma in
terms of optimal waiting time until resection. The risk of
tumor growth obviously demands as short as possible
waiting time. The time interval is mainly determined by the
time required to attain sufficient FRL volume. Usually a
period of 3–4 weeks is considered sufficient based on CT
volumetry.64 Little is known concerning the improvement
of FRL function after PVE. One study separately assessed
biliary excretion of indocyanine green by the embolized
and nonembolized liver lobes and concluded that the
functional gain in the nonembolized lobes was of greater
magnitude than the volumetric increase.6 Two additional
studies from Japan confirmed that the increase in FRL
function after PVE measured by technetium–99 m (99mTc)-
galactosyl-human serum albumin (GSA) scintigraphy
exceeds the increase in volume in cirrhotic and noncirrh-
otic patients.3,65 This implies that the recommended
waiting time until operation may be shorter than suggested
by volumetric studies, which is more favorable in light of
the risk of tumor progression after PVE.
The combination of TACE before PVE is effective in
inducing tumor necrosis and thereby in inhibiting tumor
progression after PVE.51,53,54 There is nevertheless, a risk
of massive necrosis with serious complications. The time
interval between the two procedures is therefore crucial to
safely undertake the combination. More research is needed
to define which patients benefit most from sequential
TACE and PVE and to determine the optimal time interval
between both procedures.
Neoadjuvant chemotherapy has become increasingly
important in downsizing unresectable colorectal liver
metastases and there are also data indicating its use in
initially resectable cases.66 Continuation of chemotherapy
after PVE is a concern as, during that time, regeneration of
FRL has to take place. Since the inhibitory effect of che-
motherapy on the hypertrophy response appears to be less
than previously assumed, there seems to be a place for
chemotherapy after PVE to control tumor growth in
patients with colorectal metastases, particularly in those
who previously have shown to be good responders.60,61
Systemic chemotherapy may also have the advantage of
controlling the progression of extrahepatic disease in the
waiting time until resection. This is an area for controlled
studies to further determine the role of chemotherapy after
PVE.
The high percentage of patients reported to have unre-
sectable disease after PVE, allegedly due to tumor
progression, is another issue. No studies are available
concerning the follow-up of unresectable patients after
PVE. The described effect of PVE stimulating tumor
growth raises the question of whether PVE reduces survival
in comparison with unresectable patients who did not
undergo PVE.
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In conclusion, whereas PVE is an established method to
increase the rate of patients with resectable liver tumors,
several issues need to be further clarified. PVE allows tumor
progression in both the embolized and nonembolized liver
segments. Although clinical studies clearly demonstrate that
tumor progression after PVE is possible, accurate data
regarding the risk of tumor progression after PVE are cur-
rently not available. However, the possibility of tumor
progression makes it important to minimize unnecessary
waiting time between PVE and resection. Sequential TACE
with PVE as well as post-PVE chemotherapy are promising
strategies to control tumor progression after PVE.
OPEN ACCESS This article is distributed under the terms of the
Creative Commons Attribution Noncommercial License which per-
mits any noncommercial use, distribution, and reproduction in any
medium, provided the original author(s) and source are credited.
REFERENCES
1. Abulkhir A, Limongelli P, Healey AJ, et al. Preoperative portal
vein embolization for major liver resection: a meta-analysis. Ann
Surg. 2008;247:49–57.
2. Madoff DC, Abdalla EK, Vauthey JN. Portal vein embolization
in preparation for major hepatic resection: evolution of a new
standard of care. J Vasc Interv Radiol. 2005;16:779–90.
3. Hirai I, Kimura W, Fuse A, et al. Evaluation of preoperative
portal embolization for safe hepatectomy, with special reference
to assessment of nonembolized lobe function with 99 mTc-GSA
SPECT scintigraphy. Surgery. 2003;133:495–506.
4. Kubo S, Shiomi S, Tanaka H, et al. Evaluation of the effect of
portal vein embolization on liver function by (99 m)tc-galactosyl
human serum albumin scintigraphy. J Surg Res. 2002;107:113–8.
5. Nanashima A, Yamaguchi H, Shibasaki S, et al. Relationship
between CT volumetry and functional liver volume using tech-
netium–99 m galactosyl serum albumin scintigraphy in patients
undergoing preoperative portal vein embolization before major
hepatectomy: a preliminary study. Dig Dis Sci. 2006;51:1190–5.
6. Uesaka K, Nimura Y, Nagino M. Changes in hepatic lobar
function after right portal vein embolization. An appraisal by
biliary indocyanine green excretion. Ann Surg. 1996;223:77–83.
7. Farges O, Belghiti J, Kianmanesh R, et al. Portal vein emboli-
zation before right hepatectomy: prospective clinical trial. Ann
Surg. 2003;237:208–17.
8. Hemming AW, Reed AI, Howard RJ, et al. Preoperative portal
vein embolization for extended hepatectomy. Ann Surg.
2003;237:686–91.
9. Aussilhou B, Lesurtel M, Sauvanet A, et al. Right portal vein
ligation is as efficient as portal vein embolization to induce
hypertrophy of the left liver remnant. J Gastrointest Surg.
2008;12:297–303.
10. Azoulay D, Castaing D, Krissat J, et al. Percutaneous portal vein
embolization increases the feasibility and safety of major liver
resection for hepatocellular carcinoma in injured liver. Ann Surg.
2000;232:665–72.
11. Azoulay D, Castaing D, Smail A, et al. Resection of nonresec-
table liver metastases from colorectal cancer after percutaneous
portal vein embolization. Ann Surg. 2000;231:480–6.
12. Nagino M, Kamiya J, Nishio H, et al. Two hundred forty con-
secutive portal vein embolizations before extended hepatectomy
for biliary cancer: surgical outcome and long-term follow-up.
Ann Surg. 2006;243:364–72.
13. Ribero D, Abdalla EK, Madoff DC, et al. Portal vein emboliza-
tion before major hepatectomy and its effects on regeneration,
resectability and outcome. Br J Surg. 2007;94:1386–94.
14. Makuuchi M, Thai BL, Takayasu K, et al. Preoperative portal
embolization to increase safety of major hepatectomy for hilar
bile duct carcinoma: a preliminary report. Surgery. 1990;
107:521–7.
15. Abdalla EK, Barnett CC, Doherty D, et al. Extended hepatectomy
in patients with hepatobiliary malignancies with and without
preoperative portal vein embolization. Arch Surg. 2002;137:
675–80.
16. Abdalla EK, Adam R, Bilchik AJ, et al. Improving resectability
of hepatic colorectal metastases: expert consensus statement. Ann
Surg Oncol. 2006;13:1271–80.
17. Schindl MJ, Redhead DN, Fearon KC, et al. The value of residual
liver volume as a predictor of hepatic dysfunction and infection
after major liver resection. Gut. 2005;54:289–96.
18. Elias D, de BT, Roche A, et al. During liver regeneration fol-
lowing right portal embolization the growth rate of liver
metastases is more rapid than that of the liver parenchyma. Br J
Surg. 1999;86:784–8.
19. Barbaro B, Di SC, Nuzzo G, et al. Preoperative right portal vein
embolization in patients with metastatic liver disease. Metastatic
liver volumes after RPVE. Acta Radiol. 2003;44:98–102.
20. Kokudo N, Tada K, Seki M, et al. Proliferative activity of
intrahepatic colorectal metastases after preoperative hemihepatic
portal vein embolization. Hepatology. 2001;34:267–72.
21. Heinrich S, Jochum W, Graf R, et al. Portal vein ligation and
partial hepatectomy differentially influence growth of intrahe-
patic metastasis and liver regeneration in mice. J Hepatol.
2006;45:35–42.
22. Kawasaki S, Makuuchi M, Kakazu T, et al. Resection for mul-
tiple metastatic liver tumors after portal embolization. Surgery.
1994;115:674–7.
23. Jaeck D, Oussoultzoglou E, Rosso E, et al. A two-stage hepa-
tectomy procedure combined with portal vein embolization to
achieve curative resection for initially unresectable multiple and
bilobar colorectal liver metastases. Ann Surg. 2004;240:1037–49.
24. Hayashi S, Baba Y, Ueno K, et al. Acceleration of primary liver
tumor growth rate in embolized hepatic lobe after portal vein
embolization. Acta Radiol. 2007;48:721–7.
25. Imamura H, Shimada R, Kubota M, et al. Preoperative portal vein
embolization: an audit of 84 patients. Hepatology. 1999;29:1099–
105.
26. Di Stefano DR, de BT, Denys A, et al. Preoperative percutaneous
portal vein embolization: evaluation of adverse events in 188
patients. Radiology. 2005;234:625–30.
27. Alwayn IP, Verbesey JE, Kim S, et al. A critical role for matrix
metalloproteinases in liver regeneration. J Surg Res. 2008;145:
192–8.
28. Mook OR, Frederiks WM, Van Noorden CJ. The role of gela-
tinases in colorectal cancer progression and metastasis. Biochim
Biophys Acta. 2004;1705:69–89.
29. Taub R. Liver regeneration: from myth to mechanism. Nat Rev
Mol Cell Biol. 2004;5:836–47.
30. Nabeshima K, Shimao Y, Inoue T, et al. Hepatocyte growth
factor/scatter factor induces not only scattering but also cohort
migration of human colorectal-adenocarcinoma cells. Int J Can-
cer. 1998;78:750–9.
31. Brozek W, Bises G, Girsch T, et al. Differentiation-dependent
expression and mitogenic action of interleukin–6 in human colon
carcinoma cells: relevance for tumour progression. Eur J Cancer.
2005;41:2347–54.
32. Otte JM, Schmitz F, Kiehne K, et al. Functional expression of
HGF and its receptor in human colorectal cancer. Digestion.
2000;61:237–46.
Tumor Progression After PVE 429
33. Fazekas K, Csuka O, Ko¨ves I, et al. Experimental and clinico-
pathologic studies on the function of the HGF receptor in human
colon cancer metastasis. Clin Exp Metastasis. 2000;18:639–49.
34. Shimizu Y, Suzuki H, Nimura Y, et al. Elevated mitochondrial
gene expression during rat liver regeneration after portal vein
ligation. Hepatology. 1995;22:1222–9.
35. Starkel P, Horsmans Y, Sempoux C, et al. After portal branch
ligation in rat, nuclear factor kappaB, interleukin-6, signal
transducers and activators of transcription 3, c-fos, c-myc, and c-
jun are similarly induced in the ligated and nonligated lobes.
Hepatology. 1999;29:1463–70.
36. Uemura T, Miyazaki M, Hirai R, et al. Different expression of
positive and negative regulators of hepatocyte growth in growing
and shrinking hepatic lobes after portal vein branch ligation in
rats. Int J Mol Med. 2000;5:173–9.
37. Kollmar O, Corsten M, Scheuer C, et al. Portal branch ligation
induces a hepatic arterial buffer response, microvascular remod-
eling, normoxygenation, and cell proliferation in portal blood-
deprived liver tissue. Am J Physiol Gastrointest Liver Physiol.
2007;292:G1534–42.
38. Harris AL. Hypoxia—a key regulatory factor in tumour growth.
Nat Rev Cancer. 2002;2:38–47.
39. Semenza GL. Hypoxia and cancer. Cancer Metastasis Rev.
2007;26:223–4.
40. Xu Y, Pasche B. TGF-beta signaling alterations and susceptibility
to colorectal cancer. Hum Mol Genet. 2007;16 Spec no 1:R14–20.
41. Rocheleau B, Ethier C, Houle R, et al. Hepatic artery buffer
response following left portal vein ligation: its role in liver tissue
homeostasis. Am J Physiol. 1999;277:G1000–7.
42. Lautt WW. Mechanism and role of intrinsic regulation of hepatic
arterial blood flow: hepatic arterial buffer response. Am J Physiol.
1985;249:G549–56.
43. Kito Y, Nagino M, Nimura Y. Doppler sonography of hepatic
arterial blood flow velocity after percutaneous transhepatic portal
vein embolization. AJR Am J Roentgenol. 2001;176:909–12.
44. Yokoyama Y, Wawrzyniak A, Sarmadi AM, et al. Hepatic arte-
rial flow becomes the primary supply of sinusoids following
partial portal vein ligation in rats. J Gastroenterol Hepatol.
2006;21:1567–74.
45. Mueller L, Goettsche J, Abdulgawad A, et al. Tumor growth-
promoting cellular host response during liver atrophy after portal
occlusion. Liver Int. 2005;25:994–1001.
46. Bajou K, Noel A, Gerard RD, et al. Absence of host plasminogen
activator inhibitor 1 prevents cancer invasion and vascularization.
Nat Med. 1998;4:923–8.
47. Tanaka S, Akaike T, Fang J, et al. Antiapoptotic effect of haem
oxygenase-1 induced by nitric oxide in experimental solid
tumour. Br J Cancer. 2003;88:902–9.
48. Jozkowicz A, Was H, Dulak J. Heme oxygenase-1 in tumors: is it
a false friend? Antioxid Redox Signal. 2007;9:2099–117.
49. Busserolles J, Megias J, Terencio MC, et al. Heme oxygenase-1
inhibits apoptosis in Caco-2 cells via activation of Akt pathway.
Int J Biochem Cell Biol. 2006;38:1510–7.
50. Ciocca DR, Calderwood SK. Heat shock proteins in cancer:
diagnostic, prognostic, predictive, and treatment implications.
Cell Stress Chaperones. 2005;10:86–103.
51. Aoki T, Imamura H, Hasegawa K, et al. Sequential preoperative
arterial and portal venous embolizations in patients with hepa-
tocellular carcinoma. Arch Surg. 2004;139:766–74.
52. Yamakado K, Takeda K, Matsumura K, et al. Regeneration of the
un-embolized liver parenchyma following portal vein emboliza-
tion. J Hepatol. 1997;27:871–80.
53. Nakao N, Miura K, Takahashi H, et al. Hepatocellular carcinoma:
combined hepatic, arterial, and portal venous embolization.
Radiology. 1986;161:303–7.
54. Ogata S, Belghiti J, Farges O, et al. Sequential arterial and portal
vein embolizations before right hepatectomy in patients with
cirrhosis and hepatocellular carcinoma. Br J Surg. 2006;93:
1091–8.
55. Yamakado K, Nakatsuka A, Tanaka N, et al. Long-term follow-
up arterial chemoembolization combined with transportal ethanol
injection used to treat hepatocellular carcinoma. J Vasc Interv
Radiol. 1999;10:641–7.
56. Vetelainen R, Dinant S, van VA, et al. Portal vein ligation is as
effective as sequential portal vein and hepatic artery ligation in
inducing contralateral liver hypertrophy in a rat model. J Vasc
Interv Radiol. 2006;17:1181–8.
57. Vogl TJ, Mack MG, Balzer JO, et al. Liver metastases: neoad-
juvant downsizing with transarterial chemoembolization before
laser-induced thermotherapy. Radiology. 2003;229:457–64.
58. Nabil M, Gruber T, Yakoub D, et al. Repetitive transarterial
chemoembolization (TACE) of liver metastases from renal cell
carcinoma: local control and survival results. Eur Radiol.
2008;18:1456–63.
59. Vogl TJ, Zangos S, Eichler K, et al. Colorectal liver metastases:
regional chemotherapy via transarterial chemoembolization
(TACE) and hepatic chemoperfusion: an update. Eur Radiol.
2007;17:1025–34.
60. Beal IK, Anthony S, Papadopoulou A, et al. Portal vein embol-
isation prior to hepatic resection for colorectal liver metastases
and the effects of periprocedure chemotherapy. Br J Radiol.
2006;79:473–8.
61. Goere D, Farges O, Leporrier J, et al. Chemotherapy does not
impair hypertrophy of the left liver after right portal vein
obstruction. J Gastrointest Surg. 2006;10:365–70.
62. Covey AM, Brown KT, Jarnagin WR, et al. Combined portal vein
embolization and neoadjuvant chemotherapy as a treatment
strategy for resectable hepatic colorectal metastases. Ann Surg.
2008;247:451–5.
63. Selzner N, Pestalozzi BC, Kadry Z, et al. Downstaging colorectal
liver metastases by concomitant unilateral portal vein ligation and
selective intra-arterial chemotherapy. Br J Surg. 2006;93:587–92.
64. Abdalla EK, Hicks ME, Vauthey JN. Portal vein embolization:
rationale, technique and future prospects. Br J Surg. 2001;88:
165–75.
65. Nishiyama Y, Yamamoto Y, Hino I, et al. 99mTc galactosyl
human serum albumin liver dynamic SPET for pre-operative
assessment of hepatectomy in relation to percutaneous transhe-
patic portal embolization. Nucl Med Commun. 2003;24:809–17.
66. Benoist S, Nordlinger B. Neoadjuvant treatment before resection
of liver metastases. Eur J Surg Oncol. 2007;33(Suppl 2):
S35–41.
430 W. de Graaf et al.
